SANTA MONICA, Calif., July 27, 2017 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced that Roger Crystal, M.D., Chief Executive Officer of Opiant, was featured this morning on Fox & Friends. The recurring segment, titled “Addiction in America,” details various aspects of the addiction crisis in the United States. Dr. Crystal was interviewed by Fox & Friends host Ainsley Earhardt. The focus of the discussion was the national opioid epidemic, what Opiant is doing to help and the advantages of NARCAN® Nasal Spray. Additionally, Dr. Crystal discussed Opiant’s product pipeline, which includes products in development for both Alcohol Use Disorder and Opioid Use Disorder.
Fox & Friends is a weekday morning news show hosted by Fox News Channel that features hosts Ainsley Earhardt, Steve Doocy and Brain Kilmeade. Regular features include medical contributors, reports from entertainment correspondents and interviews with newsmakers. Please click here to view the segment.
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
CONTACT INFORMATION: Corporate Contact: [email protected] Investors: Sam Martin Argot Partners [email protected] 212-600-1902


FDA Approves Mitapivat for Anemia in Thalassemia Patients
Italy Fines Apple €98.6 Million Over App Store Dominance
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 



